Trial Profile

A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of ZSP1241 in Participants With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ZSP 1241 (Primary)
Indications Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Liver cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions
Sponsors Guangdong Zhongsheng Pharmaceutical

Most Recent Events

20 Jul 2020 Planned End Date changed from 20 Nov 2020 to 31 Oct 2021.
20 Jul 2020 Planned primary completion date changed from 20 Oct 2020 to 31 Oct 2021.
18 Feb 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com